SOPHiA GENETICS (Nasdaq: SOPH) has announced that Dhiti Omics Technologies, a leading provider of precision molecular diagnostics in India, has integrated the SOPHiA DDM™ Platform to enhance its solid tumor testing capabilities. Specializing in molecular diagnostic and genetic testing, Dhiti Omics will leverage SOPHiA GENETICS’ technology, specifically the SOPHiA DDM™ for Agilent SureSelect Cancer CGP application. This integration aims to empower researchers with actionable insights into mutations and biomarkers across numerous genes.
Dr. Sudha N. Rao, Founder and Director of Dhiti Omics Technologies, expressed enthusiasm for advancing precision medicine in India and globally. By combining high-quality reagents with powerful analytics through SOPHiA DDM™, Dhiti Omics aims to optimize comprehensive genomic profiling data interpretation, ensuring swift and accurate diagnostics for their clientele.
The SureSelect Cancer CGP application, launched in 2023, combines Agilent’s genomic profiling assay kit with SOPHiA DDM™ AI Platform, facilitating comprehensive genomic profiling aligned with latest biomarker guidelines. Ricardo Mendonca Filho, Managing Director, LAPAC at SOPHiA GENETICS, highlighted how their platform supports Dhiti Omics in accelerating precision medicine, particularly in solid tumor testing for the Indian population.
The collaboration between Agilent and SOPHiA GENETICS enables Dhiti Omics to pioneer new approaches in cancer research and diagnostics. SOPHiA GENETICS, a cloud-native healthcare technology company, leverages AI to provide data-driven medicine globally, focusing on cancer and rare disorders. Their SOPHiA DDM™ Platform analyzes complex genomic and multimodal data, delivering real-time insights to a network of hospitals, laboratories, and biopharma institutions.